科伦博泰生物-B(06990)今日盘中大涨5.02%,引起了市场的广泛关注。
消息面上,公司发布公告称,其用于治疗复发或转移性鼻咽癌的创新药物塔戈利单抗注射液(科泰莱)已获国家药品监督管理局批准在中国上市。这一阶段性里程碑事件反映了公司在医药创新领域的进展,为鼻咽癌患者提供了新的治疗选择方案。
塔戈利单抗是一种人源化单克隆抗体,可特异性结合细胞程序性死亡配体-1,阻断其与程序性死亡受体-1的相互作用,从而恢复免疫细胞对肿瘤细胞的抑制作用。该品种上市前景广阔,有望为公司创造新的利润增长点。市场对此表示了积极评价,导致公司股价在盘中出现明显上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.